{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T16:19:36Z","timestamp":1790785176456,"version":"4.1.0"},"reference-count":138,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T00:00:00Z","timestamp":1539820800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH107487"],"award-info":[{"award-number":["MH107487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["MH107916"],"award-info":[{"award-number":["MH107916"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ES006096"],"award-info":[{"award-number":["ES006096"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HL127624"],"award-info":[{"award-number":["HL127624"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1TR001425"],"award-info":[{"award-number":["UL1TR001425"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["MH107487"],"award-info":[{"award-number":["MH107487"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Local Initiative for Excellence Foundation"},{"name":"CIHR Operating Grant","award":["119298"],"award-info":[{"award-number":["119298"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Neurobiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s12035-018-1390-4","type":"journal-article","created":{"date-parts":[[2018,10,18]],"date-time":"2018-10-18T11:24:50Z","timestamp":1539861890000},"page":"4492-4517","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":44,"title":["Connectivity Analyses of Bioenergetic Changes in Schizophrenia: Identification of Novel Treatments"],"prefix":"10.1007","volume":"56","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9267-1060","authenticated-orcid":false,"given":"Courtney R.","family":"Sullivan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine A.","family":"Mielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinead M.","family":"O\u2019Donovan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam J.","family":"Funk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eduard","family":"Bentea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica A.","family":"DePasquale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Alganem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhexing","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahram","family":"Haroutunian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavel","family":"Katsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarek","family":"Meller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert E.","family":"McCullumsmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,10,18]]},"reference":[{"key":"1390_CR1","volume-title":"Diagnostic and statistical manual of mental disorders","author":"Association AP","year":"2000","unstructured":"Association AP (2000) Diagnostic and statistical manual of mental disorders, 4th, text revision edn. American Psychiatric Association, Washington, D.C.","edition":"4th, text revis"},{"key":"1390_CR2","first-page":"1096","volume-title":"Comprehensive textbook of psychiatry","author":"RW Buchanan","year":"2000","unstructured":"Buchanan RW, Carpenter WT (2000) Schizophrenia: introduction and overview. In: Sadock BJ, Sadock VA (eds) Comprehensive textbook of psychiatry, vol 1. Lippincott, Williams, and Wilkins, Philadelphia, pp. 1096\u20131110"},{"issue":"1","key":"1390_CR3","first-page":"12","volume":"26","author":"W Fleischhacker","year":"2000","unstructured":"Fleischhacker W (2000) Negative symptoms in patients with schizophrenia with special reference to the primary versus secondary distinction. L\u2019Encephale 26(1):12\u201314","journal-title":"L\u2019Encephale"},{"issue":"1\u20132","key":"1390_CR4","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.psychres.2007.10.006","volume":"165","author":"A Zanello","year":"2009","unstructured":"Zanello A, Curtis L, Badan Ba M, Merlo MC (2009) Working memory impairments in first-episode psychosis and chronic schizophrenia. Psychiatry Res 165(1\u20132):10\u201318","journal-title":"Psychiatry Res"},{"issue":"1","key":"1390_CR5","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/schbul\/sbn162","volume":"35","author":"SG Potkin","year":"2009","unstructured":"Potkin SG, Turner JA, Brown GG, McCarthy G, Greve DN, Glover GH, Manoach DS, Belger A et al (2009) Working memory and DLPFC inefficiency in schizophrenia: the FBIRN study. Schizophr Bull 35(1):19\u201331","journal-title":"Schizophr Bull"},{"issue":"1\u20133","key":"1390_CR6","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.schres.2008.06.001","volume":"105","author":"T Wobrock","year":"2008","unstructured":"Wobrock T, Schneider M, Kadovic D, Schneider-Axmann T, Ecker UK, Retz W, R\u00f6sler M, Falkai P (2008) Reduced cortical inhibition in first-episode schizophrenia. Schizophr Res 105(1\u20133):252\u2013261","journal-title":"Schizophr Res"},{"issue":"2","key":"1390_CR7","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1093\/oxfordjournals.schbul.a033376","volume":"25","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25(2):233\u2013255","journal-title":"Schizophr Bull"},{"issue":"24","key":"1390_CR8","doi-asserted-by":"publisher","first-page":"13591","DOI":"10.1073\/pnas.96.24.13591","volume":"96","author":"HY Meltzer","year":"1999","unstructured":"Meltzer HY, Park S, Kessler R (1999) Cognition, schizophrenia, and the atypical antipsychotic drugs. Proc Natl Acad Sci 96(24):13591\u201313593","journal-title":"Proc Natl Acad Sci"},{"issue":"3","key":"1390_CR9","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/0896-6273(95)90304-6","volume":"14","author":"PS Goldman-Rakic","year":"1995","unstructured":"Goldman-Rakic PS (1995) Cellular basis of working memory. Neuron 14(3):477\u2013485","journal-title":"Neuron"},{"issue":"1","key":"1390_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/npp.2013.239","volume":"39","author":"RE McCullumsmith","year":"2014","unstructured":"McCullumsmith RE, Hammond JH, Shan D, Meador-Woodruff JH (2014) Postmortem brain: an underutilized substrate for studying severe mental illness. Neuropsychopharmacology. 39(1):65\u201387","journal-title":"Neuropsychopharmacology."},{"key":"1390_CR11","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/mp.2015.148","volume":"6","author":"RE McCullumsmith","year":"2016","unstructured":"McCullumsmith RE, O\u2019Donovan SM, Drummond JB, Benesh FS, Simmons M, Roberts R, Lauriat T, Haroutunian V et al (2016) Cell-specific abnormalities of glutamate transporters in schizophrenia: sick astrocytes and compensating relay neurons? Mol Psychiatry 6:823\u2013830","journal-title":"Mol Psychiatry"},{"key":"1390_CR12","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/S0074-7742(04)59002-5","volume":"59","author":"R McCullumsmith","year":"2004","unstructured":"McCullumsmith R, Clinton S, Meador-Woodruff J (2004) Schizophrenia as a disorder of neuroplasticity. Int Rev Neurobiol 59:19\u201345","journal-title":"Int Rev Neurobiol"},{"key":"1390_CR13","doi-asserted-by":"crossref","unstructured":"Sullivan CR, O\u2019Donovan S, McCullumsmith RE, Ramsey A (2017) Defects in bioenergetic coupling in schizophrenia. Biol Psychiatry","DOI":"10.1016\/j.biopsych.2017.10.014"},{"issue":"1","key":"1390_CR14","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/ajmg.b.20132","volume":"127B","author":"WS Stone","year":"2004","unstructured":"Stone WS, Faraone SV, Su J, Tarbox SI, Van Eerdewegh P, Tsuang MT (2004) Evidence for linkage between regulatory enzymes in glycolysis and schizophrenia in a multiplex sample. Am J Med Genet B Neuropsychiatr Genet 127B(1):5\u201310","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"2","key":"1390_CR15","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.biopsych.2005.03.031","volume":"58","author":"CA Altar","year":"2005","unstructured":"Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, Young TA, Bullard J et al (2005) Deficient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58(2):85\u201396","journal-title":"Biol Psychiatry"},{"issue":"11","key":"1390_CR16","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/mp.2014.171","volume":"20","author":"D Arion","year":"2015","unstructured":"Arion D, Corradi JP, Tang S, Datta D, Boothe F, He A, Cacace AM, Zaczek R et al (2015) Distinctive transcriptome alterations of prefrontal pyramidal neurons in schizophrenia and schizoaffective disorder. Mol Psychiatry 20(11):1397\u20131405","journal-title":"Mol Psychiatry"},{"issue":"8","key":"1390_CR17","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.biopsych.2017.03.018","volume":"82","author":"D Arion","year":"2017","unstructured":"Arion D, Huo Z, Enwright JF, Corradi JP, Tseng G, Lewis DA (2017) Transcriptome alterations in prefrontal pyramidal cells distinguish schizophrenia from bipolar and major depressive disorders. Biol Psychiatry 82(8):594\u2013600","journal-title":"Biol Psychiatry"},{"key":"1390_CR18","doi-asserted-by":"publisher","unstructured":"Sullivan CR, Koene RH, Hasselfeld K, O\u2019Donovan SM, Ramsey A, McCullumsmith RE (2018) Neuron-specific deficits of neuroenergetic processes in the dorsolateral prefrontal cortex in schizophrenia. Mol Psychiatry. https:\/\/doi.org\/10.1038\/s41380-018-0035-3 (in press)","DOI":"10.1038\/s41380-018-0035-3"},{"issue":"D1","key":"1390_CR19","doi-asserted-by":"publisher","first-page":"D558","DOI":"10.1093\/nar\/gkx1063","volume":"46","author":"A Koleti","year":"2018","unstructured":"Koleti A, Terryn R, Stathias V, Chung C, Cooper DJ, Turner JP, Vidovi\u0107 D, Forlin M et al (2018) Data portal for the library of integrated network-based cellular signatures (LINCS) program: integrated access to diverse large-scale cellular perturbation response data. Nucleic Acids Res 46(D1):D558\u2013Dd66","journal-title":"Nucleic Acids Res"},{"issue":"Web Server issu","key":"1390_CR20","doi-asserted-by":"publisher","first-page":"W449","DOI":"10.1093\/nar\/gku476","volume":"42","author":"Q Duan","year":"2014","unstructured":"Duan Q, Flynn C, Niepel M, Hafner M, Muhlich JL, Fernandez NF, Rouillard AD, Tan CM et al (2014) LINCS canvas browser: interactive web app to query, browse and interrogate LINCS L1000 gene expression signatures. Nucleic Acids Res 42(Web Server issue):W449\u2013WW60","journal-title":"Nucleic Acids Res"},{"key":"1390_CR21","unstructured":"Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information. Takeda Pharmaceuticals America, Inc., Deerfield, Illinois. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/99\/021073A_Actos.cfm"},{"issue":"3","key":"1390_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/S0893-133X(98)00060-8","volume":"20","author":"JD Jentsch","year":"1999","unstructured":"Jentsch JD, Roth RH (1999) The neuropsychopharmacology of phencyclidine: from NMDA receptor hypofunction to the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 20(3):201\u2013225","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"1390_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1176\/ajp.135.9.1081","volume":"135","author":"R Allen","year":"1978","unstructured":"Allen R, Young S (1978) Phencyclidine-induced psychosis. Am J Psychiatry 135(9):1081\u20131084","journal-title":"Am J Psychiatry"},{"issue":"10","key":"1390_CR24","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1176\/ajp.148.10.1301","volume":"148","author":"DC Javitt","year":"1991","unstructured":"Javitt DC, Zukin SR (1991) Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148(10):1301\u20131308","journal-title":"Am J Psychiatry"},{"issue":"2","key":"1390_CR25","doi-asserted-by":"publisher","first-page":"183","DOI":"10.2174\/1568007024606212","volume":"1","author":"JT Coyle","year":"2002","unstructured":"Coyle JT, Tsai G, Goff DC (2002) Ionotropic glutamate receptors as therapeutic targets in schizophrenia. Curr Drug Targets CNS Neurol Disord 1(2):183\u2013189","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"issue":"3","key":"1390_CR26","first-page":"363","volume":"81","author":"ED Luby","year":"1959","unstructured":"Luby ED, Cohen BD, Rosenbaum G, Gottlieb JS, Kelley R (1959) Study of a new schizophrenomimetic drug; sernyl. Schizophr Res 81(3):363\u2013369","journal-title":"Schizophr Res"},{"issue":"3","key":"1390_CR27","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","volume":"51","author":"JH Krystal","year":"1994","unstructured":"Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner JD, Heninger GR, Bowers MB Jr et al (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry 51(3):199\u2013214","journal-title":"Arch Gen Psychiatry"},{"issue":"4","key":"1390_CR28","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S0893-133X(01)00243-3","volume":"25","author":"AC Lahti","year":"2001","unstructured":"Lahti AC, Weiler MA, Tamara Michaelidis BA, Parwani A, Tamminga CA (2001) Effects of ketamine in normal and schizophrenic volunteers. Neuropsychopharmacology 25(4):455\u2013467","journal-title":"Neuropsychopharmacology"},{"issue":"3\u20134","key":"1390_CR29","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.brainresbull.2010.04.006","volume":"83","author":"JT Kantrowitz","year":"2010","unstructured":"Kantrowitz JT, Javitt DC (2010) N-methyl-d-aspartate (NMDA) receptor dysfunction or dysregulation: the final common pathway on the road to schizophrenia? Brain Res Bull 83(3\u20134):108\u2013121","journal-title":"Brain Res Bull"},{"issue":"7","key":"1390_CR30","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/S0006-3223(02)01783-3","volume":"53","author":"S Begni","year":"2003","unstructured":"Begni S, Moraschi S, Bignotti S, Fumagalli F, Rillosi L, Perez J, Gennarelli M (2003) Association between the G1001C polymorphism in the GRIN1 gene promoter region and schizophrenia. Biol Psychiatry 53(7):617\u2013619","journal-title":"Biol Psychiatry"},{"issue":"5","key":"1390_CR31","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1097\/YPG.0b013e3280c1e5fb","volume":"17","author":"A Georgi","year":"2007","unstructured":"Georgi A, Jamra RA, Klein K, Villela AW, Schumacher J, Becker T, Paul T, Schmael C et al (2007) Possible association between genetic variants at the GRIN1 gene and schizophrenia with lifetime history of depressive symptoms in a German sample. Psychiatr Genet 17(5):308\u2013310","journal-title":"Psychiatr Genet"},{"issue":"2","key":"1390_CR32","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1007\/s12031-008-9148-5","volume":"38","author":"H Galehdari","year":"2009","unstructured":"Galehdari H, Pooryasin A, Foroughmand A, Daneshmand S, Saadat M (2009) Association between the G1001C polymorphism in the GRIN1 gene promoter and schizophrenia in the Iranian population. J Mol Neurosci 38(2):178\u2013181","journal-title":"J Mol Neurosci"},{"issue":"5","key":"1390_CR33","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1097\/00008571-200305000-00006","volume":"13","author":"M Itokawa","year":"2003","unstructured":"Itokawa M, Yamada K, Yoshitsugu K, Toyota T, Suga T, Ohba H, Watanabe A, Hattori E et al (2003) A microsatellite repeat in the promoter of the N-methyl-D-aspartate receptor 2A subunit (GRIN2A) gene suppresses transcriptional activity and correlates with chronic outcome in schizophrenia. Pharmacogenetics 13(5):271\u2013278","journal-title":"Pharmacogenetics"},{"issue":"2","key":"1390_CR34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.neulet.2004.12.013","volume":"378","author":"Y Iwayama-Shigeno","year":"2005","unstructured":"Iwayama-Shigeno Y, Yamada K, Itokawa M, Toyota T, Meerabux JM, Minabe Y, Mori N, Inada T et al (2005) Extended analyses support the association of a functional (GT)n polymorphism in the GRIN2A promoter with Japanese schizophrenia. Neurosci Lett 378(2):102\u2013105","journal-title":"Neurosci Lett"},{"issue":"1","key":"1390_CR35","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.neulet.2006.09.022","volume":"409","author":"J Tang","year":"2006","unstructured":"Tang J, Chen X, Xu X, Wu R, Zhao J, Hu Z, Xia K (2006) Significant linkage and association between a functional (GT)n polymorphism in promoter of the N-methyl-D-aspartate receptor subunit gene (GRIN2A) and schizophrenia. Neurosci Lett 409(1):80\u201382","journal-title":"Neurosci Lett"},{"issue":"7","key":"1390_CR36","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/sj.ejhg.5201418","volume":"13","author":"S Qin","year":"2005","unstructured":"Qin S, Zhao X, Pan Y, Liu J, Feng G, Fu J, Bao J, Zhang Z et al (2005) An association study of the N-methyl-D-aspartate receptor NR1 subunit gene (GRIN1) and NR2B subunit gene (GRIN2B) in schizophrenia with universal DNA microarray. Eur J Hum Genet 13(7):807\u2013814","journal-title":"Eur J Hum Genet"},{"issue":"2\u20133","key":"1390_CR37","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.schres.2006.02.001","volume":"84","author":"L Martucci","year":"2006","unstructured":"Martucci L, Wong AH, De Luca V, Likhodi O, Wong GW, King N, Kennedy JL (2006) N-methyl-D-aspartate receptor NR2B subunit gene GRIN2B in schizophrenia and bipolar disorder: Polymorphisms and mRNA levels. Schizophr Res 84(2\u20133):214\u2013221","journal-title":"Schizophr Res"},{"issue":"8","key":"1390_CR38","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/ajmg.b.31234","volume":"156b","author":"D Demontis","year":"2011","unstructured":"Demontis D, Nyegaard M, Buttenschon HN, Hedemand A, Pedersen CB, Grove J, Flint TJ, Nordentoft M et al (2011) Association of GRIN1 and GRIN2A-D with schizophrenia and genetic interaction with maternal herpes simplex virus-2 infection affecting disease risk. Am J Med Genet B Neuropsychiatr Genet 156b(8):913\u2013922","journal-title":"Am J Med Genet B Neuropsychiatr Genet"},{"issue":"4","key":"1390_CR39","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1016\/S0092-8674(00)81972-8","volume":"98","author":"AR Mohn","year":"1999","unstructured":"Mohn AR, Gainetdinov RR, Caron MG, Koller BH (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98(4):427\u2013436","journal-title":"Cell"},{"key":"1390_CR40","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0079-6123(09)17906-2","volume":"179","author":"AJ Ramsey","year":"2009","unstructured":"Ramsey AJ (2009) NR1 knockdown mice as a representative model of the glutamate hypothesis of schizophrenia. Prog Brain Res 179:51\u201358","journal-title":"Prog Brain Res"},{"key":"1390_CR41","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1038\/tp.2012.69","volume":"2","author":"MJ Gandal","year":"2012","unstructured":"Gandal MJ, Sisti J, Klook K, Ortinski PI, Leitman V, Liang Y, Thieu T, Anderson R et al (2012) GABAB-mediated rescue of altered excitatory-inhibitory balance, gamma synchrony and behavioral deficits following constitutive NMDAR-hypofunction. Transl Psychiatry 2:e142","journal-title":"Transl Psychiatry"},{"key":"1390_CR42","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/2040-2392-5-38","volume":"5","author":"H Wesseling","year":"2014","unstructured":"Wesseling H, Guest PC, Lee CM, Wong EH, Rahmoune H, Bahn S (2014) Integrative proteomic analysis of the NMDA NR1 knockdown mouse model reveals effects on central and peripheral pathways associated with schizophrenia and autism spectrum disorders. Mol Autism 5:38","journal-title":"Mol Autism"},{"issue":"3","key":"1390_CR43","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1093\/schbul\/sbq132","volume":"38","author":"K Zhou","year":"2012","unstructured":"Zhou K, Yang Y, Gao L, He G, Li W, Tang K, Ji B, Zhang M et al (2012) NMDA receptor hypofunction induces dysfunctions of energy metabolism and semaphorin signaling in rats: a synaptic proteome study. Schizophr Bull 38(3):579\u2013591","journal-title":"Schizophr Bull"},{"issue":"4","key":"1390_CR44","doi-asserted-by":"publisher","first-page":"e60598","DOI":"10.1371\/journal.pone.0060598","volume":"8","author":"L Sun","year":"2013","unstructured":"Sun L, Li J, Zhou K, Zhang M, Yang J, Li Y, Ji B, Zhang Z et al (2013) Metabolomic analysis reveals metabolic disturbance in the cortex and hippocampus of subchronic MK-801 treated rats. PLoS One 8(4):e60598","journal-title":"PLoS One"},{"key":"1390_CR45","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3389\/fnint.2016.00010","volume":"10","author":"MQ Steinman","year":"2016","unstructured":"Steinman MQ, Gao V, Alberini CM (2016) The role of lactate-mediated metabolic coupling between astrocytes and neurons in long-term memory formation. Front Integr Neurosci 10:10","journal-title":"Front Integr Neurosci"},{"issue":"5","key":"1390_CR46","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.cell.2011.02.018","volume":"144","author":"A Suzuki","year":"2011","unstructured":"Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, Alberini CM (2011) Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144(5):810\u2013823","journal-title":"Cell"},{"issue":"12","key":"1390_CR47","doi-asserted-by":"publisher","first-page":"e28427","DOI":"10.1371\/journal.pone.0028427","volume":"6","author":"LA Newman","year":"2011","unstructured":"Newman LA, Korol DL, Gold PE (2011) Lactate produced by glycogenolysis in astrocytes regulates memory processing. PLoS One 6(12):e28427","journal-title":"PLoS One"},{"key":"1390_CR48","first-page":"13","volume":"121","author":"U Smith","year":"2001","unstructured":"Smith U (2001) Pioglitazone: mechanism of action. Int J Clin Pract Suppl 121:13\u201318","journal-title":"Int J Clin Pract Suppl"},{"issue":"1","key":"1390_CR49","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejphar.2007.05.070","volume":"572","author":"SW Seto","year":"2007","unstructured":"Seto SW, Lam TY, Leung GP, Au AL, Ngai SM, Chan SW, Kwan YW (2007) Comparison of vascular relaxation, lipolysis and glucose uptake by peroxisome proliferator-activated receptor-\u03b3 activation in + db\/+ m and + db\/+ db mice. Eur J Pharmacol 572(1):40\u201348","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"1390_CR50","doi-asserted-by":"publisher","first-page":"E252","DOI":"10.1152\/ajpendo.00424.2003","volume":"286","author":"JR Colca","year":"2004","unstructured":"Colca JR, McDonald WG, Waldon DJ, Leone JW, Lull JM, Bannow CA, Lund ET et al (2004) Identification of a novel mitochondrial protein (\u201cmitoNEET\u201d) cross-linked specifically by a thiazolidinedione photoprobe. Am J Physiol Endocrinol Metab 286(2):E252\u2013E260","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"36","key":"1390_CR51","doi-asserted-by":"publisher","first-page":"14342","DOI":"10.1073\/pnas.0707189104","volume":"104","author":"ML Paddock","year":"2007","unstructured":"Paddock ML, Wiley SE, Axelrod HL, Cohen AE, Roy M, Abresch EC, Capraro D, Murphy AN et al (2007) MitoNEET is a uniquely folded 2Fe 2S outer mitochondrial membrane protein stabilized by pioglitazone. Proc Natl Acad Sci U S A 104(36):14342\u201314347","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1390_CR52","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.vph.2007.01.007","volume":"46","author":"J Hwang","year":"2007","unstructured":"Hwang J, Kleinhenz DJ, Rupnow HL, Campbell AG, Thule PM, Sutliff RL, Hart CM (2007) The PPARgamma ligand, rosiglitazone, reduces vascular oxidative stress and NADPH oxidase expression in diabetic mice. Vasc Pharmacol 46(6):456\u2013462","journal-title":"Vasc Pharmacol"},{"issue":"11","key":"1390_CR53","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1210\/me.2013-1427","volume":"28","author":"MB Wright","year":"2014","unstructured":"Wright MB, Bortolini M, Tadayyon M, Bopst M (2014) Minireview: challenges and opportunities in development of PPAR agonists. Mol Endocrinol 28(11):1756\u20131768","journal-title":"Mol Endocrinol"},{"issue":"8","key":"1390_CR54","doi-asserted-by":"publisher","first-page":"5828","DOI":"10.1074\/jbc.M208132200","volume":"278","author":"C Dello Russo","year":"2003","unstructured":"Dello Russo C, Gavrilyuk V, Weinberg G, Almeida A, Bolanos JP, Palmer J, Pelligrino D, Galea E et al (2003) Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 278(8):5828\u20135836","journal-title":"J Biol Chem"},{"issue":"3","key":"1390_CR55","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.brainresbull.2010.04.008","volume":"83","author":"LC Amann","year":"2010","unstructured":"Amann LC, Gandal MJ, Halene TB, Ehrlichman RS, White SL, McCarren HS, Siegel SJ (2010) Mouse behavioral endophenotypes for schizophrenia. Brain Res Bull 83(3):147\u2013161","journal-title":"Brain Res Bull"},{"issue":"1","key":"1390_CR56","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.expneurol.2010.09.008","volume":"227","author":"NM Ben Abdallah","year":"2011","unstructured":"Ben Abdallah NM, Fuss J, Trusel M, Galsworthy MJ, Bobsin K, Colacicco G, Deacon RM, Riva MA et al (2011) The puzzle box as a simple and efficient behavioral test for exploring impairments of general cognition and executive functions in mouse models of schizophrenia. Exp Neurol 227(1):42\u201352","journal-title":"Exp Neurol"},{"issue":"14","key":"1390_CR57","doi-asserted-by":"publisher","first-page":"5795","DOI":"10.1073\/pnas.1012621108","volume":"108","author":"AJ Ramsey","year":"2011","unstructured":"Ramsey AJ, Milenkovic M, Oliveira AF, Escobedo-Lozoya Y, Seshadri S, Salahpour A, Sawa A, Yasuda R et al (2011) Impaired NMDA receptor transmission alters striatal synapses and DISC1 protein in an age-dependent manner. Proc Natl Acad Sci U S A 108(14):5795\u20135800","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"10","key":"1390_CR58","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1038\/sj.mp.4001159","volume":"7","author":"MA Geyer","year":"2002","unstructured":"Geyer MA, McIlwain KL, Paylor R (2002) Mouse genetic models for prepulse inhibition: an early review. Mol Psychiatry 7(10):1039\u20131053","journal-title":"Mol Psychiatry"},{"key":"1390_CR59","doi-asserted-by":"publisher","first-page":"e579","DOI":"10.1038\/tp.2015.74","volume":"5","author":"SM O\u2019Donovan","year":"2015","unstructured":"O\u2019Donovan SM, Hasselfeld K, Bauer D, Simmons M, Roussos P, Haroutunian V, Meador-Woodruff JH et al (2015) Glutamate transporter splice variant expression in an enriched pyramidal cell population in schizophrenia. Transl Psychiatry 5:e579","journal-title":"Transl Psychiatry"},{"issue":"7","key":"1390_CR60","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.biopsych.2011.02.022","volume":"70","author":"MS Sodhi","year":"2011","unstructured":"Sodhi MS, Simmons M, McCullumsmith R, Haroutunian V, Meador-Woodruff JH (2011) Glutamatergic gene expression is specifically reduced in thalamocortical projecting relay neurons in schizophrenia. Biol Psychiatry 70(7):646\u2013654","journal-title":"Biol Psychiatry"},{"key":"1390_CR61","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/1471-2164-7-70","volume":"7","author":"BW Higgs","year":"2006","unstructured":"Higgs BW, Elashoff M, Richman S, Barci B (2006) An online database for brain disease research. BMC Genomics 7:70","journal-title":"BMC Genomics"},{"issue":"3","key":"1390_CR62","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s11892-009-0034-5","volume":"9","author":"DN Gross","year":"2009","unstructured":"Gross DN, Wan M, Birnbaum MJ (2009) The role of FOXO in the regulation of metabolism. Curr Diab Rep 9(3):208\u2013214","journal-title":"Curr Diab Rep"},{"key":"1390_CR63","first-page":"925350","volume":"2014","author":"Y Wang","year":"2014","unstructured":"Wang Y, Zhou Y, Graves DT (2014) FOXO transcription factors: their clinical significance and regulation. Biomed Res Int 2014:925350","journal-title":"Biomed Res Int"},{"issue":"11","key":"1390_CR64","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/embor.2010.160","volume":"11","author":"H Gehart","year":"2010","unstructured":"Gehart H, Kumpf S, Ittner A, Ricci R (2010) MAPK signalling in cellular metabolism: stress or wellness? EMBO Rep 11(11):834\u2013840","journal-title":"EMBO Rep"},{"issue":"1","key":"1390_CR65","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1042\/BJ20091866","volume":"427","author":"JK Sethi","year":"2010","unstructured":"Sethi JK, Vidal-Puig A (2010) Wnt signalling and the control of cellular metabolism. Biochem J 427(1):1\u201317","journal-title":"Biochem J"},{"issue":"2","key":"1390_CR66","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1002\/hup.2517","volume":"31","author":"N Iranpour","year":"2016","unstructured":"Iranpour N, Zandifar A, Farokhnia M, Goguol A, Yekehtaz H, Khodaie-Ardakani MR, Salehi B, Esalatmanesh S et al (2016) The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial. Hum Psychopharmacol 31(2):103\u2013112","journal-title":"Hum Psychopharmacol"},{"issue":"1","key":"1390_CR67","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.schres.2012.10.023","volume":"143","author":"RC Smith","year":"2013","unstructured":"Smith RC, Jin H, Li C, Bark N, Shekhar A, Dwivedi S, Mortiere C, Lohr J et al (2013) Effects of pioglitazone on metabolic abnormalities, psychopathology, and cognitive function in schizophrenic patients treated with antipsychotic medication: a randomized double-blind study. Schizophr Res 143(1):18\u201324","journal-title":"Schizophr Res"},{"issue":"2","key":"1390_CR68","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/0009-8981(80)90210-7","volume":"103","author":"JF Koster","year":"1980","unstructured":"Koster JF, Slee RG, Van Berkel TJ (1980) Isoenzymes of human phosphofructokinase. Clin Chim Acta 103(2):169\u2013173","journal-title":"Clin Chim Acta"},{"issue":"3","key":"1390_CR69","doi-asserted-by":"publisher","first-page":"897","DOI":"10.1042\/bj1920897","volume":"192","author":"E Van Schaftingen","year":"1980","unstructured":"Van Schaftingen E, Hue L, Hers HG (1980) Fructose 2,6-bisphosphate, the probably structure of the glucose- and glucagon-sensitive stimulator of phosphofructokinase. Biochem J 192(3):897\u2013901","journal-title":"Biochem J"},{"key":"1390_CR70","doi-asserted-by":"publisher","first-page":"7838","DOI":"10.1038\/ncomms8838","volume":"6","author":"DB Graham","year":"2015","unstructured":"Graham DB, Becker CE, Doan A, Goel G, Villablanca EJ, Knights D, Mok A, Ng ACY et al (2015) Functional genomics identifies negative regulatory nodes controlling phagocyte oxidative burst. Nat Commun 6:7838","journal-title":"Nat Commun"},{"issue":"1","key":"1390_CR71","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF00283052","volume":"76","author":"KG Anner\u00e9n","year":"1987","unstructured":"Anner\u00e9n KG, Korenberg JR, Epstein CJ (1987) Phosphofructokinase activity in fibroblasts aneuploid for chromosome 21. Hum Genet 76(1):63\u201365","journal-title":"Hum Genet"},{"issue":"6163","key":"1390_CR72","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/332454a0","volume":"332","author":"M Chaput","year":"1988","unstructured":"Chaput M, Claes V, Portetelle D, Cludts I, Cravador A, Burny A, Gras H, Tartar A (1988) The neurotrophic factor neuroleukin is 90% homologous with phosphohexose isomerase. Nature 332(6163):454\u2013455","journal-title":"Nature"},{"key":"1390_CR73","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1186\/s12967-015-0540-y","volume":"13","author":"M-L Liu","year":"2015","unstructured":"Liu M-L, Zhang X-T, Du X-Y, Fang Z, Liu Z, Xu Y, Zheng P, Xu XJ et al (2015) Severe disturbance of glucose metabolism in peripheral blood mononuclear cells of schizophrenia patients: a targeted metabolomic study. J Transl Med 13:226","journal-title":"J Transl Med"},{"issue":"11","key":"1390_CR74","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1016\/j.bbadis.2011.07.007","volume":"1812","author":"JF Haller","year":"2011","unstructured":"Haller JF, Krawczyk SA, Gostilovitch L, Corkey BE, Zoeller RA (2011) Glucose-6-phosphate isomerase deficiency results in mTOR activation, failed translocation of lipin 1\u03b1 to the nucleus and hypersensitivity to glucose: implications for the inherited glycolytic disease. Biochim Biophys Acta 1812(11):1393\u20131402","journal-title":"Biochim Biophys Acta"},{"issue":"3","key":"1390_CR75","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1111\/jnc.12622","volume":"129","author":"A Gururajan","year":"2014","unstructured":"Gururajan A, van den Buuse M (2014) Is the mTOR-signalling cascade disrupted in schizophrenia? J Neurochem 129(3):377\u2013387","journal-title":"J Neurochem"},{"issue":"7527","key":"1390_CR76","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1038\/nature13716","volume":"515","author":"Z Wen","year":"2014","unstructured":"Wen Z, Nguyen HN, Guo Z, Lalli MA, Wang X, Su Y, Kim NS, Yoon KJ et al (2014) Synaptic dysregulation in a human iPS cell model of mental disorders. Nature 515(7527):414\u2013418","journal-title":"Nature"},{"issue":"5","key":"1390_CR77","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/S0898-6568(01)00271-6","volume":"14","author":"KM Nicholson","year":"2002","unstructured":"Nicholson KM, Anderson NG (2002) The protein kinase B\/Akt signalling pathway in human malignancy. Cell Signal 14(5):381\u2013395","journal-title":"Cell Signal"},{"issue":"1","key":"1390_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S1567-133X(00)00002-8","volume":"1","author":"X-M Guan","year":"2001","unstructured":"Guan X-M, Yu H, Jiang Q, Van der Ploeg LHT, Liu Q (2001) Distribution of neuromedin U receptor subtype 2 mRNA in the rat brain. Published on the World Wide Web on 27 November 2000. Gene Expr Patterns 1(1):1\u20134","journal-title":"Gene Expr Patterns"},{"issue":"1","key":"1390_CR79","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1006\/bbrc.2000.3669","volume":"277","author":"M Nakazato","year":"2000","unstructured":"Nakazato M, Hanada R, Murakami N, Date Y, Mondal MS, Kojima M, Yoshimatsu H, Kangawa K et al (2000) Central effects of neuromedin U in the regulation of energy homeostasis. Biochem Biophys Res Commun 277(1):191\u2013194","journal-title":"Biochem Biophys Res Commun"},{"issue":"18","key":"1390_CR80","doi-asserted-by":"publisher","first-page":"3890","DOI":"10.1182\/blood-2009-01-201111","volume":"114","author":"R Pal","year":"2009","unstructured":"Pal R, Janz M, Galson DL, Gries M, Li S, Johrens K, Anagnostopoulos I, Dorken B et al (2009) C\/EBPbeta regulates transcription factors critical for proliferation and survival of multiple myeloma cells. Blood 114(18):3890\u20133898","journal-title":"Blood"},{"issue":"41","key":"1390_CR81","doi-asserted-by":"publisher","first-page":"17475","DOI":"10.1073\/pnas.0908641106","volume":"106","author":"D Ruffell","year":"2009","unstructured":"Ruffell D, Mourkioti F, Gambardella A, Kirstetter P, Lopez RG, Rosenthal N, Nerlov C (2009) A CREB-C\/EBP\u03b2 cascade induces M2 macrophage-specific gene expression and promotes muscle injury repair. Proc Natl Acad Sci U S A 106(41):17475\u201317480","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"1390_CR82","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1042\/BST20130010","volume":"41","author":"RD Kelly","year":"2013","unstructured":"Kelly RD, Cowley SM (2013) The physiological roles of histone deacetylase (HDAC) 1 and 2: complex co-stars with multiple leading parts. Biochem Soc Trans 41(3):741\u2013749","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"1390_CR83","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/j.cell.2007.05.003","volume":"129","author":"George-Lucian Moldovan","year":"2007","unstructured":"Moldovan G-L, Pfander B, Jentsch S PCNA, the maestro of the replication fork. Cell 129(4):665\u2013679","journal-title":"Cell"},{"issue":"9","key":"1390_CR84","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/j.biopsych.2013.03.020","volume":"74","author":"M Jakovcevski","year":"2013","unstructured":"Jakovcevski M, Bharadwaj R, Straubhaar J, Gao G, Gavin DP, Jakovcevski I, Mitchell AC, Akbarian S (2013) Prefrontal cortical dysfunction after overexpression of histone deacetylase 1. Biol Psychiatry 74(9):696\u2013705","journal-title":"Biol Psychiatry"},{"key":"1390_CR85","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.brainres.2008.08.023","volume":"1239","author":"S Narayan","year":"2008","unstructured":"Narayan S, Tang B, Head SR, Gilmartin TJ, Sutcliffe JG, Dean B, Thomas EA (2008) Molecular profiles of schizophrenia in the CNS at different stages of illness. Brain Res 1239:235\u2013248","journal-title":"Brain Res"},{"issue":"1\u20133","key":"1390_CR86","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.schres.2007.09.020","volume":"98","author":"RP Sharma","year":"2008","unstructured":"Sharma RP, Grayson DR, Gavin DP (2008) Histone deactylase 1 expression is increased in the prefrontal cortex of schizophrenia subjects: analysis of the National Brain Databank microarray collection. Schizophr Res 98(1\u20133):111\u2013117","journal-title":"Schizophr Res"},{"issue":"3","key":"1390_CR87","doi-asserted-by":"crossref","first-page":"405","DOI":"10.31887\/DCNS.2014.16.3\/sakbarian","volume":"16","author":"S Akbarian","year":"2014","unstructured":"Akbarian S (2014) Epigenetic mechanisms in schizophrenia. Dialogues Clin Neurosci 16(3):405\u2013417","journal-title":"Dialogues Clin Neurosci"},{"issue":"7220","key":"1390_CR88","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1038\/nature07413","volume":"456","author":"V Chandra","year":"2008","unstructured":"Chandra V, Huang P, Hamuro Y, Raghuram S, Wang Y, Burris TP, Rastinejad F (2008) Structure of the intact PPAR-\u03b3\u2013RXR-\u03b1 nuclear receptor complex on DNA. Nature 456(7220):350\u2013356","journal-title":"Nature"},{"issue":"22","key":"1390_CR89","doi-asserted-by":"publisher","first-page":"12953","DOI":"10.1074\/jbc.270.22.12953","volume":"270","author":"JM Lehmann","year":"1995","unstructured":"Lehmann JM, Moore LB, Smith-Oliver TA, Wilkison WO, Willson TM, Kliewer SA (1995) An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor \u03b3 (PPAR\u03b3). J Biol Chem 270(22):12953\u201312956","journal-title":"J Biol Chem"},{"issue":"12","key":"1390_CR90","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1517\/14728220802507852","volume":"12","author":"N Muller","year":"2008","unstructured":"Muller N (2008) Inflammation and the glutamate system in schizophrenia: implications for therapeutic targets and drug development. Expert Opin Ther Targets 12(12):1497\u20131507","journal-title":"Expert Opin Ther Targets"},{"key":"1390_CR91","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/B978-0-12-398314-5.00003-9","volume":"88","author":"N Muller","year":"2012","unstructured":"Muller N, Myint AM, Schwarz MJ (2012) Inflammation in schizophrenia. Adv Protein Chem Struct Biol 88:49\u201368","journal-title":"Adv Protein Chem Struct Biol"},{"issue":"3","key":"1390_CR92","doi-asserted-by":"publisher","first-page":"213","DOI":"10.2174\/157339510791823673","volume":"6","author":"N M\u00fcller","year":"2010","unstructured":"M\u00fcller N, Schwarz MJ (2010) Immune system and schizophrenia. Curr Immunol Rev 6(3):213\u2013220","journal-title":"Curr Immunol Rev"},{"issue":"6376","key":"1390_CR93","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1126\/science.aad6469","volume":"359","author":"MJ Gandal","year":"2018","unstructured":"Gandal MJ, Haney JR, Parikshak NN, Leppa V, Ramaswami G, Hartl C, Schork AJ, Appadurai V et al (2018) Shared molecular neuropathology across major psychiatric disorders parallels polygenic overlap. Science 359(6376):693","journal-title":"Science"},{"issue":"7","key":"1390_CR94","first-page":"2463","volume":"32","author":"J-E Kurtz","year":"2012","unstructured":"Kurtz J-E, Ray-Coquard I (2012) PI3 kinase inhibitors in the clinic: an update. Anticancer Res 32(7):2463\u20132470","journal-title":"Anticancer Res"},{"issue":"Pt 2","key":"1390_CR95","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1042\/BST0350253","volume":"35","author":"T Crabbe","year":"2007","unstructured":"Crabbe T (2007) Exploring the potential of PI3K inhibitors for inflammation and cancer. Biochem Soc Trans 35(Pt 2):253\u2013256","journal-title":"Biochem Soc Trans"},{"issue":"1","key":"1390_CR96","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/jpet.106.111674","volume":"321","author":"K Ito","year":"2007","unstructured":"Ito K, Caramori G, Adcock IM (2007) Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321(1):1\u20138","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"1390_CR97","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.pharmthera.2005.10.014","volume":"110","author":"HO Kalkman","year":"2006","unstructured":"Kalkman HO (2006) The role of the phosphatidylinositide 3-kinase-protein kinase B pathway in schizophrenia. Pharmacol Ther 110(1):117\u2013134","journal-title":"Pharmacol Ther"},{"key":"1390_CR98","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.brainres.2014.04.029","volume":"1568","author":"JL McGuire","year":"2014","unstructured":"McGuire JL, Hammond JH, Yates SD, Chen D, Haroutunian V, Meador-Woodruff JH, McCullumsmith RE (2014) Altered serine\/threonine kinase activity in schizophrenia. Brain Res 1568:42\u201354","journal-title":"Brain Res"},{"key":"1390_CR99","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s40591-016-0047-9","volume":"4","author":"L Enriquez-Barreto","year":"2016","unstructured":"Enriquez-Barreto L, Morales M (2016) The PI3K signaling pathway as a pharmacological target in autism related disorders and schizophrenia. Mol Cell Ther 4:2","journal-title":"Mol Cell Ther"},{"issue":"30","key":"1390_CR100","doi-asserted-by":"publisher","first-page":"12165","DOI":"10.1073\/pnas.1206118109","volume":"109","author":"AJ Law","year":"2012","unstructured":"Law AJ, Wang Y, Sei Y, O\u2019Donnell P, Piantadosi P, Papaleo F, Straub RE, Huang W et al (2012) Neuregulin 1-ErbB4-PI3K signaling in schizophrenia and phosphoinositide 3-kinase-p110delta inhibition as a potential therapeutic strategy. Proc Natl Acad Sci U S A 109(30):12165\u201312170","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"1390_CR101","doi-asserted-by":"publisher","first-page":"4902","DOI":"10.1128\/MCB.14.7.4902","volume":"14","author":"B Cheatham","year":"1994","unstructured":"Cheatham B, Vlahos CJ, Cheatham L, Wang L, Blenis J, Kahn CR (1994) Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol Cell Biol 14(7):4902\u20134911","journal-title":"Mol Cell Biol"},{"issue":"4","key":"1390_CR102","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1093\/schbul\/21.4.567","volume":"21","author":"LB Dixon","year":"1995","unstructured":"Dixon LB, Lehman AF, Levine J (1995) Conventional antipsychotic medications for schizophrenia. Schizophr Bull 21(4):567\u2013577","journal-title":"Schizophr Bull"},{"issue":"5","key":"1390_CR103","first-page":"86","volume":"114","author":"BD Tsygankov","year":"2014","unstructured":"Tsygankov BD, Agasarain EG, Zykova AS (2014) Antipsychotic drugs and their influence on the carbohydrate metabolism in patients with schizophrenia-spectrum disorders. Zh Nevrol Psikhiatr Im S S Korsakova 114(5):86\u201391","journal-title":"Zh Nevrol Psikhiatr Im S S Korsakova"},{"issue":"4","key":"1390_CR104","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/S1059-1311(95)80003-4","volume":"4","author":"JA Davies","year":"1995","unstructured":"Davies JA (1995) Mechanisms of action of antiepileptic drugs. Seizure 4(4):267\u2013271","journal-title":"Seizure"},{"issue":"Suppl 2","key":"1390_CR105","first-page":"74","volume":"37","author":"L Citrome","year":"2003","unstructured":"Citrome L (2003) Schizophrenia and valproate. Psychopharmacol Bull 37(Suppl 2):74\u201388","journal-title":"Psychopharmacol Bull"},{"key":"1390_CR106","doi-asserted-by":"crossref","unstructured":"Schwarz C, Volz A, Li C, Leucht S (2008) Valproate for schizophrenia. Cochrane Database Syst Rev (3):Cd004028","DOI":"10.1002\/14651858.CD004028.pub3"},{"issue":"16","key":"1390_CR107","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1007\/s00018-007-7079-x","volume":"64","author":"G Rosenberg","year":"2007","unstructured":"Rosenberg G (2007) The mechanisms of action of valproate in neuropsychiatric disorders: can we see the forest for the trees? Cell Mol Life Sci 64(16):2090\u20132103","journal-title":"Cell Mol Life Sci"},{"issue":"15","key":"1390_CR108","doi-asserted-by":"publisher","first-page":"10505","DOI":"10.1074\/jbc.274.15.10505","volume":"274","author":"CE Juge-Aubry","year":"1999","unstructured":"Juge-Aubry CE, Hammar E, Siegrist-Kaiser C, Pernin A, Takeshita A, Chin WW, Burger AG, Meier CA (1999) Regulation of the transcriptional activity of the peroxisome proliferator-activated receptor alpha by phosphorylation of a ligand-independent trans-activating domain. J Biol Chem 274(15):10505\u201310510","journal-title":"J Biol Chem"},{"issue":"1","key":"1390_CR109","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.bcp.2014.07.018","volume":"92","author":"L Wang","year":"2014","unstructured":"Wang L, Waltenberger B, Pferschy-Wenzig E-M, Blunder M, Liu X, Malainer C, Blazevic T, Schwaiger S et al (2014) Natural product agonists of peroxisome proliferator-activated receptor gamma (PPAR\u03b3): a review. Biochem Pharmacol 92(1):73\u201389","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"1390_CR110","first-page":"3250","volume":"86","author":"A Aljada","year":"2001","unstructured":"Aljada A, Garg R, Ghanim H, Mohanty P, Hamouda W, Assian E, Dandona P (2001) Nuclear factor-kappaB suppressive and inhibitor-kappaB stimulatory effects of troglitazone in obese patients with type 2 diabetes: evidence of an antiinflammatory action? J Clin Endocrinol Metab 86(7):3250\u20133256","journal-title":"J Clin Endocrinol Metab"},{"issue":"9 Suppl 6","key":"1390_CR111","doi-asserted-by":"publisher","first-page":"S148","DOI":"10.1002\/dme.1996.13.s6.148","volume":"13","author":"RR Henry","year":"1996","unstructured":"Henry RR (1996) Effects of troglitazone on insulin sensitivity. Diabet Med 13(9 Suppl 6):S148\u2013S150","journal-title":"Diabet Med"},{"key":"1390_CR112","doi-asserted-by":"crossref","unstructured":"Perez MJ, Quintanilla RA (2015) Therapeutic actions of the thiazolidinediones in Alzheimer\u2019s disease. PPAR Res (2015):8","DOI":"10.1155\/2015\/957248"},{"issue":"8","key":"1390_CR113","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1111\/j.1755-5949.2012.00341.x","volume":"18","author":"L-Y Jiang","year":"2012","unstructured":"Jiang L-Y, Tang S-S, Wang X-Y, Liu L-P, Long Y, Hu M, Liao MX, Ding QL et al (2012) PPAR\u03b3 agonist pioglitazone reverses memory impairment and biochemical changes in a mouse model of type 2 diabetes mellitus. CNS Neurosci Ther 18(8):659\u2013666","journal-title":"CNS Neurosci Ther"},{"issue":"2","key":"1390_CR114","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/ana.24439","volume":"78","author":"MT Heneka","year":"2015","unstructured":"Heneka MT, Fink A, Doblhammer G (2015) Effect of pioglitazone medication on the incidence of dementia. Ann Neurol 78(2):284\u2013294","journal-title":"Ann Neurol"},{"key":"1390_CR115","doi-asserted-by":"publisher","first-page":"e448","DOI":"10.1038\/cddis.2012.189","volume":"3","author":"F Masciopinto","year":"2012","unstructured":"Masciopinto F, Di Pietro N, Corona C, Bomba M, Pipino C, Curcio M, Di Castelnuovo A, Ciavardelli D et al (2012) Effects of long-term treatment with pioglitazone on cognition and glucose metabolism of PS1-KI, 3xTg-AD, and wild-type mice. Cell Death Dis 3:e448","journal-title":"Cell Death Dis"},{"issue":"7","key":"1390_CR116","doi-asserted-by":"publisher","first-page":"e68612","DOI":"10.1371\/journal.pone.0068612","volume":"8","author":"P Papadopoulos","year":"2013","unstructured":"Papadopoulos P, Rosa-Neto P, Rochford J, Hamel E (2013) Pioglitazone improves reversal learning and exerts mixed cerebrovascular effects in a mouse model of Alzheimer\u2019s disease with combined amyloid-\u03b2 and cerebrovascular pathology. PLoS One 8(7):e68612","journal-title":"PLoS One"},{"issue":"9","key":"1390_CR117","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","volume":"32","author":"T Sato","year":"2011","unstructured":"Sato T, Hanyu H, Hirao K, Kanetaka H, Sakurai H, Iwamoto T (2011) Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease. Neurobiol Aging 32(9):1626\u20131633","journal-title":"Neurobiol Aging"},{"issue":"1","key":"1390_CR118","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.expneurol.2010.10.003","volume":"227","author":"A Sauerbeck","year":"2011","unstructured":"Sauerbeck A, Gao J, Readnower R, Liu M, Pauly JR, Bing G, Sullivan PG (2011) Pioglitazone attenuates mitochondrial dysfunction, cognitive impairment, cortical tissue loss, and inflammation following traumatic brain injury. Exp Neurol 227(1):128\u2013135","journal-title":"Exp Neurol"},{"issue":"2","key":"1390_CR119","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s00213-002-1099-x","volume":"162","author":"V Kumari","year":"2002","unstructured":"Kumari V, Sharma T (2002) Effects of typical and atypical antipsychotics on prepulse inhibition in schizophrenia: a critical evaluation of current evidence and directions for future research. Psychopharmacology 162(2):97\u2013101","journal-title":"Psychopharmacology"},{"issue":"8","key":"1390_CR120","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/gbb.12183","volume":"13","author":"M Milenkovic","year":"2014","unstructured":"Milenkovic M, Mielnik CA, Ramsey AJ (2014) NMDA receptor-deficient mice display sexual dimorphism in the onset and severity of behavioural abnormalities. Genes Brain Behav 13(8):850\u2013862","journal-title":"Genes Brain Behav"},{"issue":"3","key":"1390_CR121","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/j.pbb.2006.09.017","volume":"85","author":"GE Duncan","year":"2006","unstructured":"Duncan GE, Moy SS, Lieberman JA, Koller BH (2006) Typical and atypical antipsychotic drug effects on locomotor hyperactivity and deficits in sensorimotor gating in a genetic model of NMDA receptor hypofunction. Pharmacol Biochem Behav 85(3):481\u2013491","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"1390_CR122","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1007\/s00213-005-0214-1","volume":"184","author":"GE Duncan","year":"2006","unstructured":"Duncan GE, Moy SS, Lieberman JA, Koller BH (2006) Effects of haloperidol, clozapine, and quetiapine on sensorimotor gating in a genetic model of reduced NMDA receptor function. Psychopharmacology 184(2):190\u2013200","journal-title":"Psychopharmacology"},{"issue":"2","key":"1390_CR123","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbr.2005.05.012","volume":"163","author":"RL Fradley","year":"2005","unstructured":"Fradley RL, O\u2019Meara GF, Newman RJ, Andrieux A, Job D, Reynolds DS (2005) STOP knockout and NMDA NR1 hypomorphic mice exhibit deficits in sensorimotor gating. Behav Brain Res 163(2):257\u2013264","journal-title":"Behav Brain Res"},{"issue":"7","key":"1390_CR124","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1111\/j.1601-183X.2009.00504.x","volume":"8","author":"TB Halene","year":"2009","unstructured":"Halene TB, Ehrlichman RS, Liang Y, Christian EP, Jonak GJ, Gur TL, Blendy JA, Dow HC et al (2009) Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia. Genes Brain Behav 8(7):661\u2013675","journal-title":"Genes Brain Behav"},{"issue":"1","key":"1390_CR125","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0920-9964(98)00145-5","volume":"37","author":"MA Lee","year":"1999","unstructured":"Lee MA, Jayathilake K, Meltzer HY (1999) A comparison of the effect of clozapine with typical neuroleptics on cognitive function in neuroleptic-responsive schizophrenia. Schizophr Res 37(1):1\u201311","journal-title":"Schizophr Res"},{"issue":"W1","key":"1390_CR126","doi-asserted-by":"publisher","first-page":"W90","DOI":"10.1093\/nar\/gkw377","volume":"44","author":"MV Kuleshov","year":"2016","unstructured":"Kuleshov MV, Jones MR, Rouillard AD, Fernandez NF, Duan Q, Wang Z, Koplev S, Jenkins SL et al (2016) Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res 44(W1):W90\u2013W97","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"1390_CR127","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","volume":"18","author":"F Iorio","year":"2013","unstructured":"Iorio F, Rittman T, Ge H, Menden M, Saez-Rodriguez J (2013) Transcriptional data: a new gateway to drug repositioning? Drug Discov Today 18(7):350\u2013357","journal-title":"Drug Discov Today"},{"issue":"6","key":"1390_CR128","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/j.cell.2017.10.049","volume":"171","author":"A Subramanian","year":"2017","unstructured":"Subramanian A, Narayan R, Corsello SM, Peck DD, Natoli TE, Lu X, Gould J, Davis JF et al (2017) A next generation connectivity map: L1000 platform and the first 1,000,000 profiles. Cell 171(6):1437\u20131452 e17","journal-title":"Cell"},{"issue":"5795","key":"1390_CR129","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1126\/science.1132939","volume":"313","author":"J Lamb","year":"2006","unstructured":"Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP et al (2006) The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 313(5795):1929\u20131935","journal-title":"Science"},{"issue":"6235","key":"1390_CR130","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1126\/science.1262110","volume":"348","author":"GT Consortium","year":"2015","unstructured":"Consortium GT (2015) Human genomics. The Genotype-Tissue Expression (GTEx) pilot analysis: multitissue gene regulation in humans. Science 348(6235):648\u2013660","journal-title":"Science"},{"issue":"6","key":"1390_CR131","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1002\/syn.20623","volume":"63","author":"RC Roberts","year":"2009","unstructured":"Roberts RC, Roche JK, Conley RR, Lahti AC (2009) Dopaminergic synapses in the caudate of subjects with schizophrenia: relationship to treatment response. Synapse 63(6):520\u2013530","journal-title":"Synapse"},{"issue":"1","key":"1390_CR132","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3168\/jds.2013-7189","volume":"97","author":"JA Appuhamy","year":"2014","unstructured":"Appuhamy JA, Nayananjalie WA, England EM, Gerrard DE, Akers RM, Hanigan MD (2014) Effects of AMP-activated protein kinase (AMPK) signaling and essential amino acids on mammalian target of rapamycin (mTOR) signaling and protein synthesis rates in mammary cells. J Dairy Sci 97(1):419\u2013429","journal-title":"J Dairy Sci"},{"issue":"5","key":"1390_CR133","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.molcel.2009.11.025","volume":"36","author":"C Cohen-Saidon","year":"2009","unstructured":"Cohen-Saidon C, Cohen AA, Sigal A, Liron Y, Alon U (2009) Dynamics and variability of ERK2 response to EGF in individual living cells. Mol Cell 36(5):885\u2013893","journal-title":"Mol Cell"},{"issue":"5","key":"1390_CR134","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1016\/j.molcel.2009.11.018","volume":"36","author":"L Goentoro","year":"2009","unstructured":"Goentoro L, Shoval O, Kirschner MW, Alon U (2009) The incoherent feedforward loop can provide fold-change detection in gene regulation. Mol Cell 36(5):894\u2013899","journal-title":"Mol Cell"},{"issue":"5","key":"1390_CR135","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1016\/j.molcel.2009.11.017","volume":"36","author":"L Goentoro","year":"2009","unstructured":"Goentoro L, Kirschner MW (2009) Evidence that fold-change, and not absolute level, of beta-catenin dictates Wnt signaling. Mol Cell 36(5):872\u2013884","journal-title":"Mol Cell"},{"key":"1390_CR136","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1186\/1471-2105-14-128","volume":"14","author":"EY Chen","year":"2013","unstructured":"Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, Clark NR, Ma\u2019ayan A (2013) Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool. BMC Bioinformatics 14:128","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"1390_CR137","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.bbr.2006.07.030","volume":"176","author":"SS Moy","year":"2007","unstructured":"Moy SS, Nadler JJ, Young NB, Perez A, Holloway LP, Barbaro RP, Barbaro JR, Wilson LM et al (2007) Mouse behavioral tasks relevant to autism: phenotypes of 10 inbred strains. Behav Brain Res 176(1):4\u201320","journal-title":"Behav Brain Res"},{"issue":"7","key":"1390_CR138","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/gbb.12155","volume":"13","author":"CA Mielnik","year":"2014","unstructured":"Mielnik CA, Horsfall W, Ramsey AJ (2014) Diazepam improves aspects of social behaviour and neuron activation in NMDA receptor-deficient mice. Genes Brain Behav 13(7):592\u2013602","journal-title":"Genes Brain Behav"}],"container-title":["Molecular Neurobiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12035-018-1390-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12035-018-1390-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,4]],"date-time":"2022-09-04T02:00:28Z","timestamp":1662256828000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12035-018-1390-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10,18]]},"references-count":138,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["1390"],"URL":"https:\/\/doi.org\/10.1007\/s12035-018-1390-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/338392","asserted-by":"object"}]},"ISSN":["0893-7648","1559-1182"],"issn-type":[{"value":"0893-7648","type":"print"},{"value":"1559-1182","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,10,18]]},"assertion":[{"value":"6 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 October 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}